Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.86
-7.44 (-3.23%)
AAPL  271.40
+1.70 (0.63%)
AMD  254.84
-9.49 (-3.59%)
BAC  53.03
+0.45 (0.86%)
GOOG  281.90
+6.73 (2.45%)
META  666.47
-85.20 (-11.33%)
MSFT  525.76
-15.79 (-2.92%)
NVDA  202.89
-4.15 (-2.00%)
ORCL  256.89
-18.41 (-6.69%)
TSLA  440.10
-21.41 (-4.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.